Emerging research suggest Retatrutide , a dual agonist targeting both the gut-brain axis and GIP , could represent a notable advancement for obesity treatment. Preliminary human tests have demonstrated impressive reductions in abdominal mass , conceivably exceeding other obesity medications . Despite this, additional study is necessary to completel